Pacific Edge Limited is one of New Zealand’s most successful biotechnology companies. It listed on the

New Zealand Stock Exchange (NZX) in 2002 and entered the NZX 50 Index ranked 38 in September 2020.  Pacific Edge has a current market capitalisation of approximately NZ$850M.  It has successfully developed and commercialised a suite of four molecular diagnostic products.  This includes a commercial portfolio of Cxbladder® cancer diagnostic products involving a non-invasive urine test that utilises genotypic and phenotypic biomarkers to quickly and accurately detect or rule out bladder cancer in patients undergoing initial investigation or post-treatment surveillance of the disease.  

Pacific Edge’s commercial products seek to address a number of important shortcomings in the clinical pathway for bladder cancer detection and management including the need for earlier detection, non-invasive testing, the ability to rule out non-cancer patients who present with symptoms, as well as offering significantly greater accuracy, repeatability and reliability.

In 2020, Pacific Edge concluded a commercial relationship with Kaiser Permanente, the largest integrated health provider in the United States with more than 12.4 million lives under coverage, for use of Cxbladder® products by its physicians within its network of 714 medical offices and 39 hospitals. This was followed shortly thereafter by another commercial agreement in the United States for insurance coverage by the Centers for Medicare and Medicaid Services (CMS) for reimbursement for Medicare.  The CMS provides insurance coverage for US citizens over the age of 65 years.  In 2021, Pacific Edge also announced the positive coverage decision for United Healthcare’s Medicare Advantage Policy for Cxbladder tests. United Healthcare is the largest healthcare group in the United States with 50 million lives under and over 14% of the US healthcare insurance market.

Pacific Edge’s success has been recognised through several industry awards including The NZ Innovators Award 2013, NZBIO Biotech Company of the Year Award 2014, Medical Technology Association of

New Zealand Innovation Award 2016 and TIN Top 10 Hot Emerging Companies in 2016 and 2017.

Catalyst Intellectual Property works closely with Pacific Edge providing high-level IP strategy advice and managing an extensive portfolio of proprietary intellectual property rights including in excess of 300 patents and 40 registered trade marks across multiple jurisdictions.